CCIA
MACK

Campbell & Co Investment Adviser’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Campbell & Co Investment Adviser’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-24,682
Closed -$111K – 915
2019
Q3 		$111K Buy
+24,682
New +$123K 0.04% 574

Other funds holding MACK

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.99B AUM 22.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Campbell & Co Investment Adviser's MACK Position: Q4 2019 in Review

Campbell & Co Investment Adviser sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2019, closing a stake of 24,682 shares — an estimated $111K sold.

Campbell & Co Investment Adviser first reported a position in MACK in Q3 2019 and held it in 1 quarter. The position peaked at $111K in Q3 2019. 48 funds tracked by Wall St. Rank hold MACK as of Q4 2019.

  • Campbell & Co Investment Adviser reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 24,682 Merrimack Pharmaceuticals, Inc. shares in Q4 2019, an estimated $111K.
  • Campbell & Co Investment Adviser first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2019 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Merrimack Pharmaceuticals, Inc. position peaked at $111K in Q3 2019.
  • 48 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2019.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2019, filed 23 Jan 2020.